NeoGenomics, Inc. (NEO) Given Average Recommendation of “Buy” by Analysts

Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus rating of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $10.00.

NEO has been the topic of several research reports. Janney Montgomery Scott reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Thursday, October 26th. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research report on Thursday, October 5th. BidaskClub cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 13th. Gabelli initiated coverage on NeoGenomics in a research report on Thursday, August 24th. They set a “buy” rating and a $9.00 price objective on the stock. Finally, BTIG Research cut NeoGenomics from a “buy” rating to a “neutral” rating in a research report on Monday, September 11th.

Several hedge funds have recently added to or reduced their stakes in NEO. Wrapmanager Inc. purchased a new position in shares of NeoGenomics during the second quarter valued at approximately $109,000. KCG Holdings Inc. purchased a new position in shares of NeoGenomics during the first quarter valued at approximately $118,000. Empirical Finance LLC purchased a new position in shares of NeoGenomics during the third quarter valued at approximately $159,000. Campbell & CO Investment Adviser LLC lifted its holdings in shares of NeoGenomics by 64.0% during the third quarter. Campbell & CO Investment Adviser LLC now owns 21,544 shares of the medical research company’s stock valued at $240,000 after purchasing an additional 8,404 shares during the last quarter. Finally, OLD National Bancorp IN lifted its holdings in shares of NeoGenomics by 38.2% during the third quarter. OLD National Bancorp IN now owns 21,714 shares of the medical research company’s stock valued at $242,000 after purchasing an additional 6,004 shares during the last quarter. Hedge funds and other institutional investors own 83.73% of the company’s stock.

NeoGenomics (NASDAQ NEO) traded down $0.06 during midday trading on Thursday, hitting $9.15. The company had a trading volume of 363,087 shares, compared to its average volume of 343,931. The company has a quick ratio of 1.99, a current ratio of 2.14 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $734.94, a PE ratio of 182.80, a PEG ratio of 11.43 and a beta of 0.85. NeoGenomics has a 12 month low of $7.12 and a 12 month high of $11.63.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $0.01 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.01. The company had revenue of $63.05 million for the quarter, compared to analysts’ expectations of $63.11 million. NeoGenomics had a positive return on equity of 3.97% and a negative net margin of 4.78%. NeoGenomics’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned $0.04 earnings per share. equities analysts anticipate that NeoGenomics will post 0.04 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “NeoGenomics, Inc. (NEO) Given Average Recommendation of “Buy” by Analysts” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2017/12/07/neogenomics-inc-neo-given-average-recommendation-of-buy-by-analysts.html.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply